Wegovy, a medication that contains the same main ingredient, semaglutide, as Ozempic, is FDA-approved for weight loss
GLP-1 receptor agonists obesity drugs market captured the largest revenue share of 81% in 2024 within North America, driven by high obesity prevalence, early drug approvals, and robust healthcare infrastructure
When considering any treatment, especially an injectable medication, your health and safety should be the top priority
External resources New England Journal of Medicine: GLORY-1 mazdutide Phase 3 results New England Journal of Medicine: Retatrutide Phase 2 trial for obesity Nature Medicine: Retatrutide for metabolic liver disease (MASLD) For researchers serious about optimizing their metabolic peptide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, dosage calculators, and a community of thousands who navigate these exact decisions
Interestingly, reductions in bodyweight and HbA1 c were similar in patients with improvements in liver histology (responders) and those without (non-responders), suggesting that, beyond bodyweight reduction and improvement in glucose control, other mechanisms may be involved in the beneficial effects of liraglutide
But, as with any drug, GLP-1s should be used under the close supervision of a health care professional and sourced from state-licensed pharmacies